首页> 美国政府科技报告 >Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Native Thai Infants; Conference paper
【24h】

Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Native Thai Infants; Conference paper

机译:在黄病毒 - 泰国本土婴儿中进行四价活减毒登革热疫苗的1/2期试验;会议文件

获取原文

摘要

The Walter Reed Army Institute of Research (WRAIR) has produced a tetravalent live-attenuated dengue vaccine that has been well tolerated and immunogenic in U.S. adults and Thai children. As infants are considered by many as an important age group for vaccination in dengue-endemic countries, we evaluated the vaccine in Thai flavivirus-na ve infants who are at risk for dengue.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号